Edgar Filing: YOUNG JAMES F - Form 4

YOUNG JA Form 4	MES F										
December 1	4, 2018										
FORM	ЛД								PPROVAL		
	Washington, D.C. 20549							N OMB Number:	3235-0287		
Check th if no lon subject to Section Form 4 of Form 5 obligation may con See Instri 1(b).	ger o 16. or Filed pur ons stinue.		Section Public U	SECU 16(a) of the	Estimated burden hou response	Estimated average burden hours per response 0.5					
(Print or Type	Responses)										
1. Name and Address of Reporting Person <u>*</u> YOUNG JAMES F			2. Issuer Name and Ticker or Trading Symbol NOVAVAX INC [NVAX]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last)	(First) (Middle)	3. Date of	of Earliest 7	Transaction		(Check an applicable)				
C/O NOVA FIRSTFIEI	AVAX, INC., 20 LD ROAD		(Month/ 12/13/2	Day/Year) 2018			X_ Director Officer (giv below)		6 Owner er (specify		
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)				 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 				
GAITHER	SBURG, MD 208	378					Person	wore than One K	eporting		
(City)	(State)	(Zip)	Tal	ole I - Non-	Derivative	Securities A	Acquired, Disposed	of, or Beneficia	lly Owned		
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deeme Execution any (Month/Da	Date, if	Code (Instr. 8)	4. Securiti onAcquired Disposed (Instr. 3, 4 Amount	(A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Reminder: Re	port on a separate line	e for each cla	ass of sec	urities bene	ficially own	ned directly	or indirectly.				
	·				Perso inform requir	ns who re nation con ed to resp ys a curre	spond to the colle tained in this form ond unless the fo ontly valid OMB co	n are not rm	EC 1474 (9-02)		

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transactio	orDerivative	Expiration Date	Underlying Securitie
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)

Edgar Filing: YOUNG JAMES F - Form 4

(Instr. 3)	Price of Derivative Security		(Month/Day/Year)	(Instr.	8)	Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)					
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amou Numb Shares
Stock Option (Right to buy)	\$ 2.3	12/13/2018		А		200,000		12/13/2019 <u>(1)</u>	12/13/2028	Common Stock	200,0

Reporting Owners

RelationshipReporting Owner Name / AddressDirector10% OwnerOfficerOtherDirector10% OwnerOfficerOtherYOUNG JAMES F
C/O NOVAVAX, INC.
20 FIRSTFIELD ROAD
GAITHERSBURG, MD 20878XVVVSignatures
/s/ John A. Herrmann III,
Attorney-in-Fact12/1-1/2018V

<u>**</u>Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

One hundred percent (100%) of the shares subject to this option grant under the Novavax, Inc. (the "Company") Amended and Restated

(1) 2015 Stock Incentive Plan, as amended, will vest one (1) year from the December 13, 2018 grant date subject to continued service on the Company's Board of Directors through the vesting date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.